• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva Medical

Reva touts first implant of bioresorbable scaffold in Turkey

May 16, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said today that the company launched its Fantom bioresorbable scaffold in Turkey. There are nearly 100 hospitals performing cardiac catheterizations in Istanbul, according to Reva. The San Diego, Calif.-based company highlighted Turkey as an important market for bioresorbable technologies, noting that it has a commercial distribution deal in the country with Kardionet Healthcare and […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva inks distro deal for bioresorbable scaffolds in Turkey

April 3, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) inked a distribution deal with Kardionet Healthcare & Foreign Trading to launch commercial operations in Turkey for its bioresorbable scaffold tech, the company reported today. According to the terms of the deal, Kardionet will be responsible for sales, marketing, customer training and support for Reva’s Fantom and Fantom Encore bioresorbable devices in Turkey. […]

Filed Under: Distribution, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva touts first implant of Fantom Encore bioresorbable scaffold in Switzerland

March 28, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) announced today that the company’s Fantom Encore bioresorbable vascular scaffold was used for the first time in Switzerland. The sirolimus-eluting device, which is made from Reva’s proprietary Tyrocore polymer, features a 95-micron strut profile and x-ray visibility. “Reva’s Tyrocore polymer makes Fantom Encore the most advanced bioresorbable scaffold with x-ray visibility and the […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Wall Street Beat Tagged With: Reva Medical

Reva Medical swings to black on first sales

March 9, 2018 By Brad Perriello

Reva Medical

Reva Medical (ASX:RVA) this week reported its first quarterly and annual revenues since winning CE Mark approval for its bioresorbable coronary scaffolds, swinging from red to black for the full year. San Diego-based Reva posted fourth-quarter profits of $160,000, or -10¢ per share, on sales of $28,000 for the three months ended Dec. 31, 2017. That […]

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Reva Medical

Anthem exec chairman joins Proteus board | Personnel Moves – Feb. 26, 2018

February 26, 2018 By Sarah Faulkner

Proteus Digital Health

Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. “Proteus has created a compelling solution to a problem that has plagued the pharmaceutical industry for decades: […]

Filed Under: Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Allergan, Anthem, BioCorRx, Brainstorm Cell Therapeutics, Chrono Therapeutics, infusystem, Proteus Digital Health, Reva Medical, zynosolutions

Reva Medical wins CE Mark for bioresorbable Fantom Encore scaffold

February 26, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) has won CE Mark clearance for its thin strut Fantom Encore bioresorbable, drug-eluting scaffold. The sirolimus-eluting vascular scaffold, which is made from Reva’s Tyrocore polymer, features a 95-micron strut profile and x-ray visibility. “Fantom Encore has the thinnest strut profile of any available bioresorbable scaffold in the 2.5 millimeter diameter size. A thinner […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Reva Medical

Reva implants first Fantom bioresorbable scaffold in Italy

January 25, 2018 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) said yesterday that the first Fantom bioresorbable scaffold was implanted in Italy. The sirolimus-eluting device is made using a tyrosine-derived polymer that is visible under x-ray. Data from Reva’s Fantom II clinical trial found that the device resulted in a 4.2% rate of major adverse cardiac events after 12 months and 5.6% after […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

Reva, Biotronik tout safety data for their drug-eluting bioresorbable scaffolds

November 1, 2017 By Sarah Faulkner

Despite the safety concerns plaguing Abbott‘s (NYSE:ABT) Absorb device, companies developing bioresorbable scaffolds are not discouraged. This week at the annual Transcatheter Cardiovascular Therapeutics Conference in Denver, a number of companies touted the safety data coming from clinical trials of their products. Among them were Reva Medical (ASX:RVA) and Biotronik – here’s an overview of that […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: abbott, Biotronik, Reva Medical

Reva Medical launches Fantom in Switzerland with first implant of bioresorbable scaffold

October 16, 2017 By Sarah Faulkner

Reva Medical

Reva Medical (ASX:RVA) has expanded its commercial operations into Switzerland, the company said today, with the first implant of its Fantom bioresorbable scaffold. The scaffold is made from Reva’s tyrosine-derived, radiopaque polymer, rendering Fantom visible under fluoroscopy – a characteristic that is unique to Reva’s product. Fantom also sports 125 micron struts, which have held up […]

Filed Under: Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: Reva Medical

European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds

October 12, 2017 By Sarah Faulkner

Abbott

Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions. The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Abbott Laboratories, Biotronik, Boston Scientific, Elixir Medical Corporation, Reva Medical

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS